Málstofa Lífvísindaseturs - Blóðskimun til bjargar
Málstofa Lífvísindaseturs Háskóla Íslands fimmtudaginn 16. janúar kl. 12:00 í Læknagarði, Vatnsmýrarvegi 16, stofu 343
Fyrirlesarar: Sigrún Þorsteinsdóttir MD PhD (Postdoc) og Sæmundur Rögnvaldsson MD (PhD student), Blóðskimun til bjargar, verkefni stýrt af Sigurði Yngva Kristinssyni prófessor við Læknadeild Háskóla Íslands
Titill: Blóðskimun til bjargar - Early findings of a nation-wide screening study for multiple myeloma
Ágrip: Multiple myeloma (MM) is a malignancy of bone marrow plasma cells that has, until recently, been considered incurable. MM is preceded by an asymptomatic premalignant state. Recently, survival in MM has improved dramatically due to the introduction of new therapies and studies have shown that by providing treatment at a high-risk but asymptomatic precursor stage, outcomes can be improved even further, possibly leading to a cure. However, more than 95% of MM patients are diagnosed at a far more advanced stage and cannot be provided with such early treatment. The iStopMM study (Iceland Screens Treats or Prevents Multiple Myeloma) aims to close this gap of detection by population-based screening and follow-up in a large clinical trial, evaluating the benefits and harms of screening and early treatment, while building an extensive biobank and dataset on MM and related disorders. With over 80,000 Icelanders registered to participate and around 65,000 blood samples already sent for screening, and over 1,000 bone marrow samples collected, the study is one of the largest interventional studies ever performed.
Erindið verður flutt á ensku og eru allir velkomnir